No Insurance Needed? Trump's TrumpRx Promises Lower Drug Prices
Experts say broader reform is still needed to tame US health spending

Health care costs have long weighed on American households. Bills arrive after the illness. Prices feel unpredictable. For many families, even routine prescriptions strain monthly budgets. This week, President Donald Trump stepped into that anxiety with a new approach: pay cash and use discounts outside traditional insurance plans.
At a White House event on Feb. 5, Trump unveiled TrumpRx.gov, a website listing about 40 commonly used prescription drugs at reduced cash prices. Trump called the launch one of the 'most transformative health care initiatives', saying the platform would give Americans immediate access to lower-cost medications.
The website does not sell medications directly but instead redirects users to participating pharmacies or drugmakers' sites where the discounted prices can be accessed.
Supporters see relief. Critics see a reshuffled version of existing discount programmes. Health policy experts say the platform may offer convenience for some patients but falls short of broader health care reform.
A Coupon Hub, Not a New System
TrumpRx does not overhaul the US health care system. Instead, it aggregates existing manufacturer and pharmacy discounts into one central website, allowing consumers to obtain coupon codes for participating pharmacies or buy directly from manufacturers.
The discounts are available only to cash-paying patients and cannot be used with insurance or applied toward deductibles, according to the website's FAQ.
Several health policy experts compared the platform to GoodRx, a long-running discount service. GoodRx confirmed it serves as a pricing integration partner for TrumpRx, with its discount codes accepted at over 70,000 retail and home delivery pharmacies. In short, the site adds convenience rather than structural reform.
Most Favoured Nation Pricing
Trump tied the initiative to his Most Favoured Nation (MFN) policy, which aims to ensure the US does not pay more for drugs than other countries. 'For years, politicians promised lower prices and failed,' Trump said at the event, which he attended alongside CMS Administrator Dr Mehmet Oz and National Design Studio Director Joe Gebbia. The goal, he said, is to deliver savings immediately.
How Much Cheaper Are Drugs?
Some headline prices are eye-catching. The GLP-1 prescription drug Wegovy, approved for weight loss, is listed at $149 per month, compared with an earlier list price of $1,349.
However, ABC News noted that Wegovy's price had already been voluntarily reduced to $499 in March 2025 and $199 in November after negotiations with the federal government. Other medications show savings of 50% or more, though several drugs still carry high cash prices even after discounts. Because some manufacturers had already reduced prices before TrumpRx launched, experts say it may be difficult to determine how much additional savings are directly attributable to the new website.
Fertility Drugs May Offer Real Relief
One area where the discounts appear meaningful is fertility treatment.
According to the website, the discounts include:
Gonal-F: 83%
Cetrotide: 93%
Ovidrel: 67%
Because many fertility medications have limited or inconsistent insurance coverage, patients often pay a large share of the cost out of pocket. Some health policy experts said these discounts could lower the total cost of an IVF cycle by roughly 20%, potentially making treatment more affordable for families paying cash.
Savings for Some, Not for All
Still, experts caution that the list remains small. 'TrumpRx's offerings are very limited, with fewer than 50 drugs listed,' said Rena Conti, an associate professor at Boston University's Questrom School of Business.
Patients with solid insurance coverage may still pay less through their plans. Others could lose deductible credit by paying cash. Public concern about costs remains widespread. A recent KFF survey found that two-thirds of Americans worry about affording health care, and 56% expect it to become less affordable in the coming year.
© Copyright IBTimes 2025. All rights reserved.



















